PMID- 7890531
OWN - NLM
STAT- MEDLINE
DCOM- 19950420
LR  - 20190825
IS  - 0021-1265 (Print)
IS  - 0021-1265 (Linking)
VI  - 164
IP  - 1
DP  - 1995 Jan
TI  - Serum neuron-specific enolase and immunohistochemical markers of neuroendocrine 
      differentiation in lung cancer.
PG  - 31-6
AB  - An enzyme immunoassay for serum neuron-specific enolase (NSE) was evaluated with 
      respect to analytical performance and clinical utility and compared with 
      immunohistochemical evaluation of neuroendocrine differentiation. Values obtained 
      agreed well with values obtained using a radioimmunoassay method giving a 
      correlation coefficient of 0.934. Analytical performance of the enzyme 
      immunoassay was good but the diagnostic sensitivity of 82% in extensive and 67% 
      in limited disease was insufficient for serum NSE to be of value in the diagnosis 
      of small cell lung cancer (SCLC). Serum NSE decreased significantly in 11 of 15 
      patients with SCLC following institution of chemotherapy. Classification of lung 
      cancers into SCLC and non small cell lung cancer (NSCLC) types is largely based 
      on tumour morphology. Neuroendocrine differentiation may not be morphologically 
      evident. Immunohistochemical staining of tumour tissue with markers of 
      neuroendocrine differentiation, i.e. NSE (both monoclonal and polyclonal 
      antibodies) Leu 7, Chromogranin A and P G P 9.5 was performed in both patients 
      with SCLC and NSCLC. 38 per cent of patients with NSCLC had both raised serum NSE 
      and positive NSE (polyclonal) immunoperoxidase staining of lung tissue. A further 
      35 per cent of patients showed a raised serum NSE or positive 
      immunohistochemistry but not both. The presence of two positive immunoperoxidase 
      markers in lung tissue has been suggested as an indicator of responsiveness to 
      chemotherapy in NSCLC patients. A number of factors may affect 
      immunohistochemical positivity in tissue sections and the additional use of a 
      serum marker may better define chemotherapy responsive groups.
FAU - O'Shea, P
AU  - O'Shea P
AD  - Department of Biochemistry, St. Vincent's Hospital, Dublin.
FAU - Cassidy, M
AU  - Cassidy M
FAU - Freaney, R
AU  - Freaney R
FAU - McCarthy, P
AU  - McCarthy P
FAU - Fennelly, J
AU  - Fennelly J
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Ir J Med Sci
JT  - Irish journal of medical science
JID - 7806864
RN  - 0 (Biomarkers, Tumor)
RN  - EC 4.2.1.11 (Phosphopyruvate Hydratase)
SB  - IM
MH  - Adult
MH  - Biomarkers, Tumor/*blood
MH  - Biopsy
MH  - Carcinoma, Non-Small-Cell Lung/blood/*diagnosis/pathology
MH  - Carcinoma, Small Cell/blood/*diagnosis/pathology
MH  - Female
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Lung/pathology
MH  - Lung Neoplasms/blood/*diagnosis/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Phosphopyruvate Hydratase/*blood
EDAT- 1995/01/01 00:00
MHDA- 1995/01/01 00:01
CRDT- 1995/01/01 00:00
PHST- 1995/01/01 00:00 [pubmed]
PHST- 1995/01/01 00:01 [medline]
PHST- 1995/01/01 00:00 [entrez]
AID - 10.1007/BF02968111 [doi]
PST - ppublish
SO  - Ir J Med Sci. 1995 Jan;164(1):31-6. doi: 10.1007/BF02968111.